# Wave Life Sciences

WVE-006, a GalNAc-conjugated AIMer for AATD, is the modality's lead asset; RestorAATion-2 data (May 2026) showed 64% wild-type M-AAT, a 71% reduction in toxic Z-AAT, 11.9 µM total AAT on 200 mg biweekly dosing (13.6 µM on 400 mg monthly), and editing sustained at least three months after the last dose,…

Source: https://en.bioecon.ru/companies/wave-life-sciences/
Updated: 2026-08-15

- Country: United States
- Ticker: NASDAQ:WVE

## Technologies

- [RNA editing (ADAR) therapeutics](https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/)